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Glia, a non-excitable cell type once considered merely as the connective tissue
between neurons, is nowadays acknowledged for its essential contribution to multiple
physiological processes including learning, memory formation, excitability, synaptic
plasticity, ion homeostasis, and energy metabolism. Moreover, as glia are key players
in the brain immune system and provide structural and nutritional support for neurons,
they are intimately involved in multiple neurological disorders. Recent advances have
demonstrated that glial cells, specifically microglia and astroglia, are involved in several
neurodegenerative diseases including Amyotrophic lateral sclerosis (ALS), Epilepsy,
Parkinson’s disease (PD), Alzheimer’s disease (AD), and frontotemporal dementia (FTD).
While there is compelling evidence for glial modulation of synaptic formation and
regulation that affect neuronal signal processing and activity, in this manuscript we will
review recent findings on neuronal activity that affect glial function, specifically during
neurodegenerative disorders. We will discuss the nature of each glial malfunction, its
specificity to each disorder, overall contribution to the disease progression and assess
its potential as a future therapeutic target.
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INTRODUCTION
Glia are non-neuronal cells of the nervous system which do not generate electrical impulses yet
communicate via other means such as calcium signals. Due to their lack of electrical activity,
it was previously assumed that glial cells primarily functioned as ‘‘nerve-glue’’ (Virchow, 1860)
and performed house-keeping functions for neurons; however, this concept has shifted due to
recent findings showing glia are key components in many neuronal functions that go far beyond
housekeeping (Araque et al., 1999; Buskila et al., 2019a).
Glial cells are categorized into two main groups; macroglia, which includes astrocytes,
oligodendrocytes, NG2-glia and ependymal cells, and microglia which are the resident phagocytes
of the central nervous system (CNS). Each population of glial cells is specialized for a particular
function in the central or peripheral nervous system (García-Cabezas et al., 2016), and normal
brain function depends on the interplay between neurons and the various types of glial cells. In
this review, we will focus on astrocytes and microglia.
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Main Processes Involving Glial Cells
Glia are involved in many fundamental processes in the CNS
including regulation of microcirculation (Zonta et al., 2003),
formation and pruning of synapses (Allen et al., 2012), synaptic
plasticity (Buskila and Amitai, 2010), and learning and memory
(Ben Menachem-Zidon et al., 2011). Glia are also essential for
the regulation of the blood-brain barrier (BBB; Lippmann et al.,
2012), clearance of metabolic waste during sleep (Xie et al., 2013)
and maintenance of synaptic transmission via ion homeostasis
which includes K+ clearance (Capuani et al., 2016) and uptake
of neurotransmitters (Lehre and Danbolt, 1998). Moreover, glia
plays a key role during neuroinflammation (Kékesi et al., 2019)
and their activity determines its severity and overall neurotoxic
effects (Liddelow et al., 2017).
Synapse Formation, Maintenance, and
Pruning
Glia play a key role in synapse formation and function during
development and adulthood (John Lin et al., 2017). Synapse
development can be divided into synaptogenesis, pruning, and
stabilization (Koeppen et al., 2018). Microglia and astroglia are
ideally positioned to affect these activities as they are in close
association with synapses, axons, and dendrites, which allows
them to monitor and alter synaptic functions (Perez-Alvarez
et al., 2014). Evidence suggests synapses can be formed without
glial support (Ullian et al., 2001); however, these synapses are
functionally premature. Hence, interactions between neurons
and glia are essential for synapse generation and function (Ullian
et al., 2004; Stogsdill and Eroglu, 2017).
During synaptogenesis, astrocytes play a pivotal role in
the formation and regulation of the number of synapses. This
was first recognized in retinal ganglion cells cultured in the
absence of astroglia, which formed 10-fold fewer synapses
compared to cultures containing astrocytes (Ullian et al.,
2001). Moreover, astrocyte-conditioned medium originated
from astrocytes from different brain regions, including the
midbrain, cortex, hippocampus, and cerebellum, found to
differ in their gene expression profiles, which effect their
synaptogenesis potential (Buosi et al., 2018). The formation of
synapses requires the assembly of presynaptic axon terminals
and postsynaptic dendritic processes into a functioning
unit that allows the transmission of electrochemical signals
(Priller et al., 2006; Zeng et al., 2018). This transformation
is induced by astrocytic secreted factors including EphrinA3
(Iadecola and Nedergaard, 2007; Nishida and Okabe, 2007;
Schiweck et al., 2018), thrombospondin (Christopherson
et al., 2005; Xu et al., 2010), neuroligin (Stogsdill and
Eroglu, 2017), and D-Serine (Sultan et al., 2015) which are
involved in the formation of excitatory synapses. Moreover,
astrocytes are involved in the regulation of molecules that
can modulate synaptic plasticity and long-term potentiation
(Ben Menachem-Zidon et al., 2011), including glutamate,
ATP, adenosine and lactate (Araque et al., 1998; Coco et al.,
2003; Martín et al., 2007; Sotelo-Hitschfeld et al., 2015;
Lepannetier et al., 2018; Gonçalves et al., 2019). Astrocytes
also seem to regulate the stability of synapses via direct contact,
as they are essential for the morphological maturation of
dendritic protrusions and promote their conversion into spines
(Nishida and Okabe, 2007).
In addition to their role during synaptogenesis, plasticity,
and maintenance, glial cells can remove synapses in a process
termed synaptic pruning, further supporting their role in
memory and learning processes (Jo et al., 2014). Microglial
processes are constantly scavenging the extracellular space for
pathogens and cellular debris. Throughout this surveillance
process, in which they are in contact with axons, synapses, and
dendritic spines, they phagocyte disused synapses (Lauterbach
and Klein, 2006; Paolicelli et al., 2011; Hong et al., 2016b;
Diaz-Aparicio et al., 2020; Milior et al., 2020), and therefore
prevent energy and nutrient loss that is much needed at
more active synapses. Hence, this synaptic pruning optimizes
the effectiveness of neuronal transmission and functional
plasticity in the brain and has been postulated to improve
learning and memory capability (Millán et al., 2019). Indeed,
abnormalities in synaptic pruning by microglia have been
associated with the cognitive decline that accompanies many
neurodegenerative disorders such as Alzheimer’s disease (AD;
Hong et al., 2016a).
Astrocytes have also been implicated in synapse loss and
regulation of long-term memory (Ben Menachem-Zidon et al.,
2011). A recent study showed that over-expression of the
protein Ephrin-B1 in astrocytes (that is typically linked to
synapse formation and stabilization) led to synaptic loss and a
decrease of glutamatergic signals (Koeppen et al., 2018). It is
thought that during physiological activity, Ephrin-B1 expressed
in astrocytes regulates synaptic remodeling by competing with
neuronal Ephrin-B1 and thus restricting new synapse formation
(Nikolakopoulou et al., 2016; Koeppen et al., 2018). Moreover,
Nikolakopoulou et al. (2016) suggested that astrocytic Ephrin-B1
is activated via the astrocytic STAT-3 mediated signaling
and affects EphB receptors in microglia which then triggers
microglia-mediated synaptic pruning. These recent studies
provide new insights about astrocyte-microglia communication
that can impact synaptic pruning and therefore should be
investigated as a new therapeutic target to prevent synapse loss
in neurodegenerative diseases.
Ion Homeostasis
A crucial glial function is the maintenance of the concentration
of ions in the interstitial space to allow proper synaptic
transmission (Capuani et al., 2016). Neuronal activity causes
a transitory rise in extracellular K+ concentration, which
must be cleared to avoid hyperactivity of the neuron (Chever
et al., 2010). K+ clearance takes place primarily by active
transport through astrocytic transporters and channels (termed
K+ uptake) which then transport K+ via gap junctions to
other astrocytes and back to the extracellular space, in a
process known as spatial buffering (Orkand et al., 1966; Buskila
et al., 2019a). This is an essential astrocytic function that
prevents the harmful build-up of K+ levels in the extracellular
space (Bellot-Saez et al., 2017). Impairments in astrocytic
K+ clearance are thought to contribute to hypersynchronous
oscillations (Bellot-Saez et al., 2018) and initiation of seizure
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activity in various neurological disorders as recently reviewed by
Bellot-Saez et al. (2017).
In addition to K+, glial cells are responsible for the regulation
of several other ions in the extracellular space including sodium
(via the activity of the Na+, K+-ATPase together with a plethora
of voltage-gated sodium channels; Wang et al., 2012), chloride
(Ratté and Prescott, 2011) and hydrogen (via the activity
of the Na+-HCO3 and Na+/H+ exchanger (Ghandour et al.,
2000). Moreover, glia form the glymphatic system, which is
responsible for the removal of metabolic waste products in the
brain, facilitated by Aquaporin-4 (AQP4) channels expressed in
astrocytic end-feet (Iliff et al., 2012). Astrocytic AQP4 channels
facilitate CSF-ISF exchange and thus modulate water flux
(and shrinkage) from the astrocyte to optimize the interstitial
space during neuronal activity (Nagelhus et al., 2004) and the
sleep-wake cycle (Ding et al., 2016).
Uptake of Neurotransmitters
For proper synaptic transmission, neurotransmitters
(e.g., GABA, glycine, and glutamate) must be transported away
from the synaptic cleft immediately after release. Glutamate
is the most common excitatory neurotransmitter in the brain,
however, excess glutamate residing in the extracellular space
can be neurotoxic (Ye et al., 2013). Many cells in the CNS are
involved in glutamate reuptake, but astrocytes are responsible
for the majority of this uptake (Bergles and Jahr, 1997; Lutgen
et al., 2016) with some estimates as high as 60–80% of total
glutamate uptake (Rothstein et al., 1996) via the excitatory
amino acid transporters EAAT1 and EAAT2 (Bergles and
Jahr, 1998). Hence, changes in astrocytic function to regulate
neurotransmitter uptake are prone to affect synaptic function
as well as cytotoxicity. Indeed, glutamate excitotoxicity is
implicated in some neurodegenerative diseases, for a detailed
review see Dong et al. (2009).
Neurovascular Coupling and the BBB
The BBB is a highly selective border around the cerebral
vasculature that prevents pathogens, toxic substances, red blood
cells, and leukocytes from the circulating blood to cross into
the interstitial fluid (Kanmogne et al., 2007). Astrocytes form
a crucial part of the BBB by supporting the integrity of the
tight junctions between endothelial cells and facilitating the
provision of nutrients from blood vessels (Lippmann et al., 2012).
Moreover, astrocytes regulate the constriction and dilation of
microvessels (Iadecola and Nedergaard, 2007) and thus form
the bridge in the neurovascular unit that couples the activity
of neurons, astrocytes and BBB endothelial cells (Viggars et al.,
2011). These features allow astrocytes to regulate the cerebral
blood flow (CBF) in regions of high neuronal activity that
requires more glucose and oxygen (Logothetis et al., 2001; Metea
and Newman, 2006).
Previous studies indicated a close association between aging
and the breakdown of the BBB, suggesting that impairment of
neurovascular coupling is responsible for the cognitive decline
seen in the elderly (Fabiani et al., 2014; Balbi et al., 2015) and
during neurodegenerative diseases such as AD (Fabiani et al.,
2014; Tarantini et al., 2017) and MS (Sivakolundu et al., 2020).
Metabolic Waste and the Glymphatic
System
The brain has a high metabolic rate (Attwell and Laughlin, 2001),
yet does not have a traditional lymphatic system to clear waste
products; instead, the glymphatic system, a term coined by the
Nedergaard group (Xie et al., 2013), is utilized as the functional
waste clearance system of the CNS. This glial-dependant system
facilitates the removal of metabolic by-products and soluble
proteins from the brain parenchyma via the exchange of solutes
between the interstitial fluid and the cerebrospinal fluid (Xie
et al., 2013; Wang et al., 2017). The exchange of fluids is driven
by arterial pulsation and activity of AQP4 channels expressed in
astrocytic endfeet (Iliff et al., 2012), suggesting that impairment
of the BBB function can impact waste clearance mechanisms,
induction of neuroinflammation and thus neurodegeneration, as
seen in BBB associated pathology (Yang et al., 2013). Indeed,
AQP4 knockout mice experienced a 55–65% reduction in Aβ
clearance compared to WT mice (Iliff et al., 2012). Furthermore,
a 40% reduction has been reported in aged mice compared
to young mice (Kress et al., 2014), which is consistent with
the notion that the glymphatic system is compromised with
age, while age is also the biggest risk factor for dementia and
several neurodegenerative conditions such as in late-onset AD
(Alzheimer’s disease facts and figures; Alzheimer’s Association,
2019). Sleep has also been shown to affect the glymphatic system,
with the clearance of toxic proteins during sleep occurring twice
as fast as during awake periods in mice (Xie et al., 2013).
Neuroinflammation
Neuroinflammation is an immune response to harmful stimuli in
the nervous system, triggered by infection or injury that leads to
microglia and astrocyte activation, aiming to defend the neuronal
tissue by clearing and controlling the harmful stimuli (Davalos
et al., 2005). Microglia are the resident immune cells of the CNS
and are known to actively investigate their microenvironment
using their processes (Nimmerjahn et al., 2005). During an
injury, infection, or disease state, microglia become ‘‘activated,’’
whereby they migrate towards sites of injury or infection
and initiate an inflammatory response by producing cytokines
and chemokines (Brockhaus et al., 1996). However, recent
studies showed that microglial activation can span between the
canonical pro-inflammatory response (termed M1 microglia) to
an alternative activation (termed M2), in which microglia release
anti-inflammatory cytokines (e.g., BDNF, IGF-1, and TGF-β),
and facilitate phagocytosis, tissue repair, and regeneration (Park
et al., 2016; Zhou et al., 2017). Moreover, the M2 phenotype is
associated with increased Aβ clearance in AD (Kawahara et al.,
2012), neurogenesis and higher survival rate of progenitor stem
cells (Yuan et al., 2017), indicating that shifting microglia into
the M2 phenotype is a plausible treatment in neurodegenerative
disorders, as recently suggested by Zhang et al. (2018).
However, some have argued the M1/M2 polarization model
is a conceptual deficit and needs to be reconsidered as
the categorization into ‘‘classical’’ or ‘‘alternative’’ state is an
over simplification that does not capture the heterogeneity of
microglia (for extensive reviews see Martinez and Gordon,
2014; Ransohoff, 2016). Indeed, transcriptomics has uncovered
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gene expression changes much beyond what can be appreciated
with a handful of markers. One such study looked at gene
expression profiles of mice that underwent traumatic brain injury
(TBI). Individual cells were analyzed using RNA-sequencing
to investigate if M1-like or M2-like macrophages could be
detected (Kim et al., 2016). The study found that expression
of a polarization marker was no more likely than random to
be co-expressed within the same cell, concluding that microglia
are not made up of polarized groups, but proposing that
individual macrophages undergo a wide range of activation
(Kim et al., 2016).
Like microglia, astrocytic activation is also hypothesized to
range between two poles of a spectrum. On the one side of
the spectrum, A1 activated astrocytes promote cell death, the
release of neurotoxins (i.e., IL-1β, IL-6, TNF-α, IFN-γ) and
activation of catabolic processes (Liddelow et al., 2017). On
the other side of the spectrum, A2 astrocytes are beneficial
as they provide neuroprotection by releasing antioxidants and
neurotrophic factors via activation of the JAK/STAT3 pathway
(Zamanian et al., 2012; Liddelow et al., 2017). Evidence suggests
that A1 reactive astrocytes are induced by cytokines released
from activated microglia (i.e., Il-1α, TNFα, and C1q; Zhang
et al., 2014). These activated A1 astrocytes lose the capacity to
support neuronal survival, induce the death of oligodendrocytes
and neurons and accompany many neurodegenerative diseases
such as Huntington’s disease (HD), AD and Amyotrophic lateral
sclerosis (ALS; Liddelow et al., 2017). Hence, the prevention of
A1 astrocytic formation and transformation of A1 astrocytes
towards the A2 phenotype can serve as a therapeutic target.
Although this classification provides insight towards astrocytic
heterogeneity, the categorization of activated astrocytes into
the A1/A2 model has been recently challenged and concerns
have been raised that this classification would be used as a
shortcut to imply a mechanistic understanding (Vainchtein and
Molofsky, 2020). Cunningham et al. (2019) recently suggested
that this classification is oversimplified which puts into risk the
complexity of the factors shaping astrocyte phenotype, and thus
astrocytic heterogeneity. Evidence in the field is yet to establish
whether the A1/A2 classification is suitable, with recent opinion
questioning if the grouping may be a simplification of the various
cellular states that astroglia assumes, both in diseased and healthy
states (Arranz and De Strooper, 2019).
NEURON TO GLIA COMMUNICATION
PATHWAYS
Neurotransmission via the Tripartite
Synapse
The tripartite synapse is a functional unit comprised of
a neuronal component (pre- and post-synaptic membranes)
along with an ensheathing astrocyte (Araque et al., 1999).
Evidence shows that the number of tripartite synapses varies
between brain regions, suggesting different levels of neuron-
glial communication. In the rodent brain, synapses ensheathed
by astrocytes account for 60–90% of total synapses in the
cerebellum (Xu-Friedman et al., 2001), 77% in the striatum
(Chai et al., 2017), 86% in the hippocampus (Chai et al.,
2017) and more than 90% of synapses in the barrel cortex
(Genoud et al., 2006). Although it remains unclear if tripartite
synapse numbers in rodents are comparable to humans, a
previous study shows that human astrocytes are significantly
larger and structurally more complex when compared to rodents
(Oberheim et al., 2009). However, this number may be harder
to estimate as tripartite synapses are dynamic and can change
following neuronal activity or sensory stimulation (Schipke
et al., 2008). It is not well documented how these synapses and
their associated mechanisms are affected in pathology, however,
evidence suggests that an imbalance in the tripartite synapse
activity is implicated in epilepsy and neuropsychiatric disorders
such as schizophrenia (Mitterauer, 2018).
Amplification of Neuronal Signaling via
Neuromodulation of Glial Activity
Astrocytes are functionally coupled via gap junctions comprised
of a pair of connexons which connect across intracellular
space (Nagy et al., 2001; Johnson et al., 2018) and link the
cytoplasm of two cells (Hofer and Dermietzel, 1998; Wei et al.,
2004; Wilson and Mongin, 2019). Astrocytic gap junctions have
several functions, including facilitation of electrical and chemical
communication between cells (Kettenmann and Ranson, 1988),
affecting neuronal rhythmicity in the brainstem (Kadala et al.,
2015; Condamine et al., 2018), distribution of excess K+ from
high concentration regions to low concentration areas, and
allowing transmembrane transport of small molecules to share
metabolic demands across cells (Huguet et al., 2016). This
communication method allows for astrocytes to work as a
syncytium and propagate signals through the astrocytic network
(Halassa et al., 2007). The failure of such connectivity and
dysfunction of signal propagation results in a malfunctioning
nervous system and can be a factor in the progression of
neurodegenerative disorders.
Astrocytic connectivity is also paramount for
neuronal—astrocytic communication. Previous studies showed
that neuronal activity triggers glial responses, resulting in
changes in the astrocytic Ca2+ concentration (Poskanzer and
Yuste, 2011, 2016). Astrocytes respond to neurotransmitters and
neuromodulators via activation of G-protein coupled receptors
(GPCRs) which leads to the release of 1,4,5-triphosphate that
induces Ca2+ release (Lev-Ram and Ellisman, 1995). These glial
Ca2+ signals are not restricted to a single cell and can propagate
as a calcium wave within the glial syncytium (Cornell-Bell et al.,
1990; Schipke et al., 2002) and thus amplify the original neuronal
signal, as recently proposed by Chen et al. (2019).
Neurons can modulate glial function via activation of
a wide variety of receptors for different neuromodulators,
including acetylcholine (Ach, nicotinic α/β and metabotropic
M1–4; Oikawa et al., 2005; Amar et al., 2010), histamine
(H1–3; Inagaki et al., 1989), serotonin (5-HT1,2,5,6,7;
Hirst et al., 1998), Noradrenaline (NA, α1,2-adrenoreceptors
and α1,2-adrenoreceptors; Bekar et al., 2008; Morin et al., 1997)
and dopamine (DA, D1–5; Khan et al., 2001; Wei et al., 2018). In
most cases, the neuromodulatory agent will lead to either change
in calcium signaling in astrocytes (see Figure 1) and microglia
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or alterations of the coupling ratio, affecting glia to work as
a syncitium. Indeed, recently, Ma et al. (2016) showed that
neuromodulators can signal through astrocytes by affecting their
Ca2+ oscillations to alter neuronal circuitry and consequently
behavioral output. In line with these observations, Nedergaard’s
group further demonstrated that bath application of a cocktail
of neuromodulators to cortical brain slices increased [K+]o
regardless of synaptic activity (Ding et al., 2016), suggesting
that increased [K+]o could serve as a mechanism to maximize
the impact of neuromodulators on synchronous activity and
recruitment of neurons into networks (Bellot-Saez et al., 2018;
Zupanc, 2020). Moreover, Bellot-Saez et al. (2019) recently
showed that different neuromodulators, such as 5-HT, NA,
DA, and histamine affect the astrocytic K+ clearance rate
via different pathways, establishing a synergistic mechanism
between neurons and astrocytes that promote excitability and
network oscillations. Also, Chen et al. (2019) reported that
in the hypothalamus, norepinephrine activates corticotropin-
releasing hormone (CRH) neurons to engage astrocytes via
dendritic retrograde signaling. This activation leads to astrocytic
release of ATP in upstream neurons, thus allowing CRH
neurons to amplify their dendritic signaling and control distal
presynaptic neurons.
Both noradrenaline and serotonin exhibit profound effects on
astrocytic metabolism (Cambray-Deakin et al., 1988). Adrenergic
agonists cause a disruption in astrocytic metabolism in the form
of increased ATPase activity (Kimelberg et al., 1978) and have
been shown to prime astrocytes for local circuity alterations
and changes in behavioral state (Paukert et al., 2014). Whereas
serotonin has the effect of altering K+ permeability in glial
cells of rodent astrocytes (Hösli et al., 1993). It is hypothesized
that a breakdown of communication in the adrenergic pathway
in the locus coeruleus and the serotonergic pathway in the
raphe nuclei leads to a break down in metabolic and functional
neuron-glia communication causing the degradation of neurons
in those regions, contributing to Alzheimer’s progression
(Hertz, 1989).
However, the impact of neuromodulators on glial activity
is complex and highly dependent on the receptor identity. For
example, activation of α7 nAChRs led to a decrease in the release
of pro-inflammatory cytokines such as IL-6 and TNF-α (Liu
et al., 2012; Li et al., 2013; Kalashnyk et al., 2014), an increased
expression of glial cell-derived neurotrophic factor (GDNF;
Takarada et al., 2012) and upregulation of glutamate uptake
via the glutamate/aspartate transporter (GLAST; Mashimo et al.,
2010; Morioka et al., 2014), suggesting acetylcholine promotes
neuroprotection via inhibition of microglia. On the other hand,
ACh was found to cause an increase in intracellular Ca2+
which stimulates the release of glutamate (Wang et al., 2013),
triggering GABAergic transmission in astrocytes (Banerjee et al.,
2012; Beggiato et al., 2013) and thus affecting the activity
of network oscillations. Moreover, cholinergic transmission
affects satellite glia to enwrap and support sensory peripheral
neurons that were previously deprived of nerve growth factor
(Enes et al., 2020).
Recently, Bosson et al. (2015) showed that blockade of
dopaminergic transmission in the substantia nigra increased
astrocytic calcium activity and gap junction coupling,
resembling morphological alterations of Parkinson’s disease
(PD; Bosson et al., 2015), and further indicating that
neuron-glia dopaminergic communication may play a part
in the etiology of PD. While histamine plays a critical role
in maintaining the energy balance of the CNS by regulating
glucose allocation/distribution (Jurič et al., 2011), it is
also purported to increase the excitability of neurons and
increase astrocytic uptake of Ca2+ in vitro (Jung et al.,
2000). Further exploration of the effect of neuromodulators
on astrocytic processes will enrich our understanding of
astrocyte functionality and the roles they play in healthy and
pathological states.
Neuronal Signals That Affect
Neuroinflammation
While our understanding of the neuroinflammatory process is
constantly developing it is clear that it is a common characteristic
which is preserved across several neurodegenerative diseases
(Thameem Dheen et al., 2007) including PD (Ghadery et al.,
2017), AD (Schuitemaker et al., 2013), ALS (Sargsyan et al.,
2005) and multiple sclerosis (MS; Kozela et al., 2011). A
plausible explanation for this phenotype is that the inflammatory
profile of microglia changes with age (DiSabato et al., 2016).
It is thought that microglia in the aged brain is primed, as
demonstrated by their elevated expression of inflammatory
mediators, with a reduced activation threshold and higher
levels of inflammation following activation. Moreover, once
activated, aged microglia are more resistant to regulation
(Norden and Godbout, 2013), which can be a contributing
factor to the progression of neurodegenerative diseases, as
active microglia synthesize and release neurotoxic substances
that cause further neuronal damage (Lull and Block, 2010).
In a healthy environment, activation of microglia serves as
a protective mechanism, however, due to the complex and
multifactorial nature of microglial activation, subtle changes may
lead to amplified or dysfunctional activation which is thought to
enhance neurodegenerative pathology, with cytokines presenting
at almost all disease phases (Brambilla, 2019).
Previous studies showed that glial activation is controlled by
neuronal activity, which can ‘‘turn-on’’ or ‘‘turn-off’’ signals that
either keep microglia in their resting quiescent state or activate
them into a proinflammatory state, for a detailed review see Biber
et al. (2007). One of the main agents through which neurons
affect glial activation is the CD200 glycoprotein, which inhibits
microglial priming and holds microglia in a quiescent state
(Shrivastava et al., 2012). Indeed, alterations in the distribution of
the CD200 or its glial receptor CD200R can lead to overactivation
of microglia and neuroinflammation (Hernangómez et al., 2012)
that accompany neurodegeneration (Oria et al., 2018). Other
neuronal agents that affect the course of neuroinflammation
are chemokines, such as CX3CL1, CXCR4 and CCL2 which
promotes microglial scavenging (Meucci et al., 2000; Hatori et al.,
2002; Paolicelli et al., 2014), regulation of the BBB integrity
(Rabinovich-Nikitin et al., 2016) and chemotaxis (Coughlan
et al., 2000; Conductier et al., 2010) respectively. These
chemokines activate diverse intracellular signaling pathways,
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FIGURE 1 | Neuromodulators’ impact on astrocytic calcium signaling. Schematic diagrams depicting the main signaling cascades in which the neuromodulators
Noradrenaline, Dopamine, Acetylcholine, Serotonin, and Histamine evoke calcium signals. The figure was created with the Motifolio toolkit (Motifolio Inc., Ellicott City,
MD, USA).
including PI3K, AKT, and NF-κB to regulate phagocytosis,
proliferation, and migration.
The Janus kinase/signal transducer and activator of
transcription 3 (JAK/STAT3) pathway is a common mediator of
astrocyte reactivity in neurodegenerative diseases (ND) and is
highly conserved between disease states (Ben Haim et al., 2015).
Previous studies showed that this pathway shifts astrocytes
towards the more beneficial A2 phenotype, which reduces
inflammation and astrogliosis (Okada et al., 2006). Indeed,
recently Ben Haim et al. (2015) showed that inhibition of the
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(JAK/STAT3) pathway increased the number of pathological
huntingtin aggregates in animal models for HD. On the
other hand, activation of the NF-κB pathway in glial cells
during inflammation was found to promote neurotoxicity and
neurodegeneration, reviewed by Dresselhaus and Meffert (2019).
Some molecules released by neurons are found to
have a dual effect on the development and progression
of neuroinflammation. For example, the brain-derived
neurotrophic factor (BDNF), which is released from neurons, can
either activate the JAK/STAT3 pathway, which shifts microglia
and astrocytes towards a more beneficial phenotype that reduces
inflammation and astrogliosis (Okada et al., 2006; Lund et al.,
2008; Hixson et al., 2019), or activate the receptor TrkB which
leads to activation of the NF-κB detrimental pathways (Colombo
et al., 2012). These alterations might stem from the mode
of activation, as continuous administration of BDNF or its
overexpression led to attenuation of microglial activation in a
mouse model of HD (Lund et al., 2008; Xie et al., 2010; Giampà
et al., 2013; Hixson et al., 2019), while acute administration
of BDNF increased microglial activity (Jiang et al., 2010) and
accelerated neurodegeneration (Colombo et al., 2012).
Glial recruitment and activation during neuroinflammation
are also modulated by neuronal release of neurotransmitters
(e.g., glutamate and GABA) and extracellular nucleotides, in
particular ATP and UDP (Haynes et al., 2006; Ulmann et al.,
2013). While GABA and glycine lead to a decrease in the
LPS-induced secretion of several cytokines (Kuhn et al., 2004)
and attenuation of the phagocytic activity of microglia (Carmans
et al., 2010), the neuronal release of glutamate can either
inhibit microglia activation via metabotropic receptors (Taylor
et al., 2002, 2003) or mediate glial activation via AMPA and
kainate ionotropic receptors (Hagino et al., 2004). Moreover,
the release mechanisms of ATP (non-specific release as occurs
during necrosis vs. vesicular exocytosis), were found to be
key effectors on the inflammatory pathway and are capable of
fine-tuning the glial response throughout neuroinflammation,
reviewed by Dosch et al. (2018). Given the importance of the
above signaling pathways on the progression of inflammation,
in which, even minor changes are sufficient to cause fatal
dysregulation of glial function and neurodegeneration, they
are increasingly becoming the focus in the development of
new therapeutics.
GLIAL PROCESSES WHICH ARE
AFFECTED DURING
NEURODEGENERATION
Neurodegenerative diseases are conventionally regarded as a
progressive neurological disorder associated with the loss of
specific populations of neurons. As a result, neurodegenerative
diseases such as Parkinson disease, AD, epilepsy, and ALS
have traditionally been associated with neurodegeneration of
dopaminergic, cholinergic, GABAergic and motor neurons
respectively (Davies and Maloney, 1976; Leenders et al.,
1990; Xu-Friedman et al., 2001; Buskila et al., 2019b).
However, increasing evidence suggests that glial dysfunction
may be a significant contributor to the pathology of these
diseases, as indicated in Supplementary Table S1. In this
chapter, we will summarize specific contributions of glial
dysfunction to different neurodegenerative diseases (see
also Figure 2).
Epilepsy
Epilepsy is a complex neurodegenerative disorder characterized
by recurrent seizures and includes both focal and generalized
seizures (Devinsky et al., 2013). Epilepsy can develop for several
reasons including genetic disposition (Ottman, 2005), TBI,
infections (Löscher et al., 2015), prenatal injury (Scher, 2003),
and developmental disorders (Lehéricy et al., 1995). Seizures are
thought to be caused by the synchronized firing of groups of
neurons which results from an imbalance between inhibitory
and excitatory currents (Scharfman, 2007). Therefore, previous
epilepsy research focused on neurons, however, recent evidence
indicates that glial cells are also involved in the pathology
of epilepsy.
One of the hallmarks of acquired epilepsy is glial scarring
formed by hypertrophic astrocytes (Das et al., 2012; Do
Nascimento et al., 2012), in which the gap-junction connectivity
between astrocytes is reduced (Wallraff et al., 2006). Indeed,
recently Bedner et al. (2015) showed that impairments in
astrocytic gap-junction coupling start within 4 h following
status epilepticus. In line with this study, acute brain slices
prepared from transgenic mice with coupling-deficient astrocytes
expressed spontaneous epileptiform activity and increased
synaptic transmission (Wallraff et al., 2006; Pannasch et al.,
2011). Dysfunctional astrocytes may be pivotal to the generation
and propagation of epileptic seizures (Seifert et al., 2006)
via their inability to sufficiently clear K+, as increasing
extracellular K+ concentration has been shown to increase
synchronous oscillatory activity (Bellot-Saez et al., 2018) and
induce epileptiform activity in brain slices (Gabriel et al., 2004).
K+ buffering in astrocytes is also regulated by Kir4.1 channels
which are found in astrocytic endfeet (Zurolo et al., 2012).
Indeed, the variation of the KCNJ10 gene that encodes
Kir4.1 channels has been linked to seizure susceptibility (Ferraro
et al., 2004; Wallraff et al., 2006). Moreover, dysfunctional
astrocytes with decreased expression of Kir4.1 channels displayed
impaired clearance of extracellular K+ and glutamate which
led to neuronal hyperexcitability (Patel et al., 2019). Although
there is an ongoing debate as to whether gliosis is consequential
or a causative effect of seizures (Patel et al., 2019), evidence
in support of the latter has shown that astrogliosis alone can
cause spontaneous seizures in the absence of other pathologies
(Robel et al., 2015).
It has been hypothesized for some time that astrocytic
processes grow towards synapses which release high levels of
glutamate as a mechanism to offset the spill-over and prevent
hyperexcitability (Ventura and Harris, 1999). Indeed, previous
studies found that patients with epilepsy expressed lower levels
of glutamine synthetase (GS) in the hippocampus (Petroff et al.,
2002; Eid et al., 2004), which results in accumulation of glutamate
in astrocytes and the extracellular space. Similarly, animal models
for epilepsy showed a significant reduction of GS activity during
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the chronic epileptogenic phase (Kang et al., 2006; Bidmon
et al., 2008; Hammer et al., 2008). Hence, it has been suggested
that reduction in GS activity is the main reason for increased
extracellular glutamate levels and seizure generation.
Research has established that astrocytes alter their
morphology and domain organization in neurodegenerative
disease, to the extent that there is a 10-fold increase in overlap of
astrocytic processes in mouse models of epilepsy (Golarai et al.,
2008). A recent study suggested that during the progression of
epilepsy, the tripartite synapse undergoes molecular, structural,
and functional changes in the hippocampus (Clarkson et al.,
2020). The study reported that in addition to decreased density in
GLT-1 expression, astrocyte processes increased ensheathment
at synapses in an attempt to decrease excitability by raising
the levels of glutamate uptake (Clarkson et al., 2020). Another
astrocytic mechanism that can lead to epilepsy involves the
dislocation of AQP4 water channels and reduced expression of
Kir channels in astrocytes, which affect K+ clearance and enhance
the propagation of seizures (Lee et al., 2004; Binder et al., 2006;
Seifert et al., 2006; Szu et al., 2020) These findings demonstrate
the importance of neuron-glia communication mechanisms
when considering new therapeutic targets for epilepsy.
Huntington’s Disease (HD)
HD is an inherited brain disorder characterized by the
progressive loss of selected neuronal populations within the
corticostriatal circuit and glial cell malfunction (Tong et al.,
2014; Jiang et al., 2017). One of the earliest astrocytic
dysfunctions in HD is a decrease in the expression of glutamate
transporters (Faideau et al., 2010) and a decrease in extracellular
glutamate uptake in both the striatum and cerebral cortex
(Przedborski et al., 2000; Liévens et al., 2001; Behrens et al.,
2002; Shin et al., 2005; Hassel et al., 2008; Baljit et al.,
2017). Moreover, the mutated huntingtin protein is reported
to lead to a decrease in the expression of Kir4.1 channels
and impairment of astrocytic K+ clearance capabilities (Tong
et al., 2014), leading to hyperexcitability of local striatal
neurons (Tong et al., 2014; Benraiss et al., 2016). Indeed,
restoring the expression of astrocytic Kir4.1 channels in an
HD mouse model rescued glutamate signaling, emphasizing
the importance of K+ homeostasis in the development of HD
(Jiang et al., 2016).
Recently, the Khakh group reported that astrocyte
morphology and spatial territory at the striatum are significantly
lower and precede synaptic dysfunction in an HD mouse
model (Octeau et al., 2018). Dysfunctional glial cells have
been shown to play a critical role in HD progression, as
mutant huntingtin expressing human glial progenitor cells
engrafted in healthy mice were found to impart the disease
phenotypes (Benraiss et al., 2016). Moreover, the introduction of
healthy human glial cells into transgenic HD mice significantly
increased survival rates and reduced motor deterioration,
along with the reinstatement of K+ homeostasis (Benraiss
et al., 2016). Furthermore, Garcia et al. (2019) used patient-
derived HD astrocytes to demonstrate that the dysfunction
of these cells leads to less astrocytic support and decreased
protection from glutamate toxicity, suggesting astrocytic
malfunction should be regarded as a major therapeutic
target in HD.
Amyotrophic Lateral Sclerosis (ALS)
ALS is the most common type of motor neuron disease, affecting
the brain and spinal cord and causing progressive loss of the
upper and lower motor neurons controlling muscle movement,
breathing, and speech (Martin et al., 2017). Astrocytes are
thought to contribute to the progression of ALS through the
abnormal function of glutamate transporters and extracellular
K+ concentration, leading to elevated levels of extracellular
glutamate and excitotoxicity (Rothstein et al., 1995; Do-Ha
et al., 2018). Indeed, SOD1 mutations that are thought to
facilitate oxidative stress (Barber et al., 2006) and are typically
found in patients who suffer from the familial form of ALS
(Tang et al., 2019) were accompanied with reduced expression
of EAAT2 transporters in astrocytes (Pedersen et al., 1998).
Moreover, Gong et al. (2000) showed that the expression of
mutated SOD1 must exist in both neurons and astrocytes
for ALS to progress, and expression of mutated SOD1 in
neurons alone was not sufficient to trigger ALS (Pramatarova
et al., 2001). Although, other in vivo studies do indicate
that transplanted glial-restricted precursor cells in wild-type
rats are sufficient to induce motor neuron death (Papadeas
et al., 2011). This is evidence that ALS is not a disease of
astrocytes or neurons alone, and that both cell types are
involved in the pathogenesis of ALS (Rothstein et al., 1995;
Do-Ha et al., 2018).
Frontotemporal Dementia
Frontotemporal dementia (FTD) is the most common type of
dementia for those aged 65 and under (Hogan et al., 2016) and
is characterized by atrophy of the frontal anterior temporal lobes
(Broe et al., 2004). Although the role astrocytes play in FTD
is not fully understood, a meta-analysis of FTD cases revealed
that astrocytic cell death increased as the disease progressed,
while neuronal apoptosis remained constant (Broe et al., 2004).
These studies indicate that the neurodegeneration seen in FTD
may be facilitated by the loss of astrocytic support. Indeed,
a recent study conducted by Hallmann et al. (2017) showed
that FTD astrocytes demonstrated changes in whole-genome
expression including upregulation of genes linked with synapse
organization and transmission (CHRNA1). Moreover, decreased
expression of EAAT2 has also been observed in the frontal
cortex of FTD patients compared with controls (Umoh et al.,
2018), suggesting that deficiencies in astrocytic glutamate uptake
may contribute to excitotoxicity and neuronal degeneration
(see Figure 2).
FTD progression is accompanied by protein alterations,
neuroinflammation, and vascular dysfunction (Martinac
et al., 2001; Garbuzova-Davis et al., 2012), which profoundly
involve microglia and astrocytes (Philips and Robberecht,
2011). Indeed, microglial activation has been associated
with neuronal loss and TAU deposition suggesting
that such microglial activation occurs in the early
stages of the disease (Schofield et al., 2003). Moreover,
autopsy samples from FTD patients expressed high
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FIGURE 2 | Glial pathophysiology during neurodegeneration. (A) Schematic representation of the relationship between neurons and glial cells, including astrocytes,
oligodendrocytes, and microglia. (B–G) Graphic illustration of the molecular and cellular processes affecting astrocytes, microglia, and oligodendrocytes during
Alzheimer’s disease (AD; C), Epilepsy (F), Frontotemporal dementia (FTD; E), Parkinson’s disease (PD; D), Huntington disease (G), and amyotrophic lateral sclerosis
(ALS; B).
levels of reactive astrocytes showing signs of degradation
which would likely contribute to neuronal cell death
(Su et al., 2000).
One of the hallmarks in FTD patients is a reduction of the
resting CBF in the frontal, temporal and parietal cortices (Dopper
et al., 2016), which is correlated with astrocytic damage and
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astrogliosis (Martinac et al., 2001). As evidence suggests that
altered cerebral perfusion may be an early biomarker of FTD
and may even show distinct perfusion patterns (Hu et al., 2010),
therapeutics aimed at maintaining cerebral circulation, to retain
astrocytic and neuronal health, maybe a beneficial future target.
Parkinson’s Disease
PD is the second most common neurodegenerative disease (de
Lau and Breteler, 2006) with symptoms including resting tremor
and bradykinesia (Salarian et al., 2007). PD is characterized by
the loss of dopaminergic neurons in the substantia nigra pars
compacta (SNpc) and the formation of α-syn deposits known as
Lewy bodies (Kordower et al., 2013; Diniz et al., 2019). Recently,
Bosson et al. (2015) reported an increase in the number of
glutamatergic synapses, which was accompanied by alterations
in astrocytic morphology in the SNr of a rat model to PD.
Moreover, intracerebroventricular injection of α-syn increased
the number of astrocytes, the density of excitatory synapses,
and the levels of TGF-b1 in the striatum of injected animals
(Diniz et al., 2019). Similarly, astrocytic spatial territories were
found to be larger in the striatum of parkinsonian monkeys
(Villalba and Smith, 2011), suggesting that astrocytic remodeling
is a compensatory mechanism aiming to decrease the high
extracellular glutamate levels and overall neuronal hyperactivity
observed in PD.
Neurodegeneration of dopaminergic neurons has also been
associated with alteration in the glial antioxidative system. Solano
et al. (2008) showed that dysfunction of the PD-associated
protein Parkin can lead to a decrease in the synthesis of
the antioxidant glutathione (GSH) by astrocytes, underlying
the lower levels of GSH found in PD patients (Baillet et al.,
2010). Indeed, previous studies indicate that the prevention of
oxidative stress protected dopaminergic neurons in an animal
model of PD (Chen et al., 2009; Kitamura et al., 2011), further
supporting the role of glial malfunction in the degeneration of
dopaminergic neurons.
It is well established that glial cells of post-mortem PD
patients show high levels of α-syn accumulation (Wakabayashi
et al., 2000). Direct neuron-glia transmission plays an essential
role in the progression of PD via the release of α-syn at axon
terminal sites where the α-syn is taken-up into astrocytes,
triggering an inflammatory response (Lee et al., 2010). It is
generally thought that astrocytes remove α-syn from the synapse
as a protective mechanism (Booth et al., 2017), however, a
recent study postulates that astrocytes amplify PD pathology by
accumulating and spreading α-syn to neighboring dopamine-
producing neurons and thus intensifying neurodegeneration (di
Domenico et al., 2019). Indeed, cultured neurons originated
from healthy individuals were more susceptible to neuronal
death once they were in contact with iPSC-derived astrocytes
from a PD patient. However, when healthy astrocytes were
cultured with PD patient neurons, α-syn did not accumulate
and neuronal function was restored (di Domenico et al., 2019).
These studies highlight the role that malfunctioning astrocytes
play in the spread of α-syn, accumulating abnormal levels due
to impaired protein degradation which may enhance the spread
of PD in the brain. As the SNpc region has the lowest astrocyte
to neuron ratio in the CNS (Damier et al., 1993), this may
explain why dopaminergic neurons are susceptible to PD as
they have less astrocytic support than neurons in other regions
(de Majo et al., 2020).
Alzheimer’s Disease
AD, the most prevalent form of dementia worldwide (Ferri et al.,
2005), is a progressive neurodegenerative disorder characterized
by the build-up of β-amyloid (Aβ) plaques, intracellular
neurofibrillary tangles (NFTs) with hyper-phosphorylated tau
and activated glial cells surrounding senile plaques (Morley
et al., 2018). Aβ deposits and tau are primarily derived from
neurons, however, the genes associated with the development
of late-onset Alzheimer’s, including apolipoprotein (APOE),
apolipoproteinJ (APOJ) and sortilin-related-receptor-1 (SORL)
are mainly expressed by glial cells (Arranz and De Strooper,
2019), suggesting that both glia and neurons are involved in
the pathogenesis of the disease. Moreover, a recent report by
Habib et al. (2020) identified a population of disease-associated
astrocytes in an AD mouse model, which appeared at early
disease stages and increased with disease progression.
Aβ deposits in the brain lead to early loss of synapses and
neurons (Buskila et al., 2013), abnormal activation of microglia,
and oxidative stress (Leyns et al., 2019). Recently, Beth Stevens’
group reported that phagocytic microglia mediate synaptic loss
in the early stages of AD via the complement system, indicating
an abnormal activation of the synaptic pruning pathway (Hong
et al., 2016b). Moreover, there is growing evidence that
glutamatergic communication between neurons and astrocytes
at the tripartite synapse is affected during AD progression, as Aβ
leads to increased glutamate release from neurons and astrocytes
(Pirttimaki et al., 2013; Talantova et al., 2013). Previous studies
in an animal model for AD demonstrated that astrocytes in the
entorhinal cortex, prefrontal cortex, and hippocampus undergo
morphological and functional alterations. These changes include
a decrease in the number of astrocytes expressing the enzyme
glutamine synthase, atrophy, and a reduction in the surface
area, volume, and complexity of astrocytic processes (Olabarria
et al., 2011; Beauquis et al., 2013, 2014; Kulijewicz-Nawrot et al.,
2013). Moreover, astrocytes at the pre-symptomatic AD phase
exhibited a decrease in vesicle trafficking (Stenovec et al., 2016),
as well as lower expression of AQP4 and GLT-1, which results
in the disruption of water and glutamate homeostasis (Hoshino
et al., 2017) and an increase of glutamate release from astrocytes,
leading to hyperexcitability and cell death (Buskila et al., 2005;
Pirttimaki et al., 2013; Talantova et al., 2013).
Multiple Sclerosis
Multiple sclerosis (MS) is a disease in which the myelin
sheath of axons degenerates, resulting in a wide range
of symptoms and functional impairments including pain,
muscle weakness, and tremors (Trapp et al., 1998). The
canonical view of this disease progression is that CD4+
T-lymphocytes cross the BBB into the parenchyma which
causes a cascade of several events leading to inflammatory
lesion and demyelination (Laplaud et al., 2004; Bahbouhi
et al., 2009). However, a secondary hypothesis states that the
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disease is neurally initiated and begins in the CNS, caused by
metabolic changes affecting neurons and glia which leads to BBB
breakdown (Chaudhuri and Behan, 2004). Although somewhat
controversial, evidence supporting this theory suggests that
neuronal loss and inflammation are present at the very early
stages of MS (Filippi et al., 2003). If it is the case that MS begins in
the CNS, neuroprotective interventions may be effective as future
MS treatments. However, the autoimmune vs. CNS-derived
theories of MS are still the source of an ongoing debate in
the literature.
The classification of different neurodegenerative diseases
is based on certain neurological symptoms expressed in
each disorder, however, there is considerable clinical and
pathological comorbidity across neurodegenerative disorders.
Patients with FTD may present with ALS or parkinsonian
syndromes and vice versa (Lomen-Hoerth et al., 2002; Padovani
et al., 2007). Also, major risk factors that lead to glial
malfunction, such as cardiovascular dysfunction, TBI, and stroke
are common in different neurodegenerative diseases, suggesting




The brain has a disproportionate energy demand relative to its
size. While it constitutes only 2% of the total body weight, it
requires 20% of the oxygen and glucose metabolism (Sokoloff,
1991). Hence, regulation of energy metabolism is essential to
maintain proper brain function, see review by Watts et al. (2018).
In the adult brain, both neurons and glia use glucose as an energy
substrate, however, a small portion of glucose molecules in the
brain is stored as glycogen chains preferentially within astrocytes
(Obel et al., 2012).
Glycogen storage in the adult brain is highly
compartmentalized, with the highest levels in the hippocampus,
striatum, and superficial layers of the cortex (Oe et al., 2016).
Immunohistochemical studies showed that glycogen has a
punctate distribution localized predominantly in astrocytic
processes (Oe et al., 2016; Hirase et al., 2019). These studies
further indicated an astrocytic heterogeneity, whereas some
astrocytes were ‘‘glycogen-rich’’ while others found to
be glycogen-poor. Further investigation of the functional
compartmentalization of glycogen stores in astrocytes showed
that glycogen granules are preferentially located in astrocytic
processes around synapses and blood vessels, rather than
randomly distributed in the astrocytic cytosol (Calì et al.,
2016; Mohammed et al., 2018). This distribution suggests that
astrocytic glycogen plays a role in synaptic processes.
Historically, astrocytic glycogen was considered to be
an emergency fuel, which is mobilized only once there
is discontinuation in the cerebral glucose supply. However,
glycogen content in the CNS is low (8–12 µmol/g tissue in
the rat brain; Cruz and Dienel, 2002), and can support brain
function only for a few minutes under ischemic conditions
(Swanson et al., 1989). Recent studies suggest that glycogen
metabolism is associated with different brain functions including
the regulation of awake-sleep cycles and high cognitive processes
such as learning and memory consolidation (Kong et al., 2002;
Gibbs et al., 2007; Gibbs and Hutchinson, 2012; Gibbs, 2016;
Bellesi et al., 2018). Moreover, glycogen is a precursor for
glutamate and glutamine synthesis (Sickmann et al., 2005; Gibbs
et al., 2007) and is found to play a neuroprotective role, as it
protects neurons from stress conditions including hypoglycemia
or hypoxic stress (Obel et al., 2012; Öz et al., 2015; Adeva-Andany
et al., 2016).
Glycogen metabolism in astrocytes is actively regulated
by neuromodulators, which activates adenyl cyclase and
increases intracellular calcium levels (Sorg and Magistretti,
1992; Cardinaux and Magistretti, 1996; Sickmann et al., 2009;
Obel et al., 2012; Dinuzzo et al., 2013; Xu et al., 2014).
Classical studies by Pierre Magistretti’s group found that
neuromodulators such as vasoactive intestinal peptide (VIP),
histamine and NA, induce glycogenolysis (the breakdown of
glycogen) in astrocytes and lead to a local increase of ATP
within the stimulated networks in a concentration-dependent
manner (Magistretti et al., 1981; Magistretti and Schorderet,
1984; Magistretti and Morrison, 1988). In line with this
work, in vivo studies involving photostimulation of the retina,
confirmed that sensory stimulation is associated with glial
glycogenolysis (Tsacopoulos et al., 1988; Poitry-Yamate and
Tsacopoulos, 1991). Moreover, glycogenolysis was detected in
the somatosensory cortex of awake rats immediately after
sensory stimulation of the vibrissae, further supporting the
impact of neuromodulators on energy metabolism (Poitry-
Yamate and Tsacopoulos, 1991; Swanson et al., 1992; Dienel
et al., 2007). In contrast, under conditions of low glutamatergic
and monoaminergic activity (e.g., anesthesia; slow-wave sleep),
glycogen levels increase (Folbergrová et al., 1970; Watanabe
and Passonneau, 1973; Karnovsky et al., 1983; Morgenthaler
et al., 2006; Bellesi et al., 2018), suggesting that glycogen is
mostly used during intense neuronal activity. Consistent with
this hypothesis, Gibbs and Hutchinson (2012) showed that NA
affects glycogen turnover to enhance memory consolidation
and glycogen-derived lactate was found to be central to higher
cognitive function and memory formation (Newman et al., 2011;
Suzuki et al., 2011).
However, the impact of neuromodulators on astrocytic
glycogen metabolism is complex and highly dependent on
the identity of the receptors. For example, while activation
of the hippocampal β1-adrenergic receptor was found to
induce glycogenolysis during the transition between the first
and second phases of intermediate memory, after 30 min it
caused α2-adrenoreceptors to induce glycogen synthesis (Gibbs
et al., 2007; Hutchinson et al., 2011; Gibbs and Hutchinson,
2012). Similar to noradrenaline, vasoactive intestinal polypeptide
(VIP) in addition to its glycogenolytic effect, was also
found to elicit temporally-delayed resynthesis of glycogen
(Sorg and Magistretti, 1991).
Given the impact of neuromodulators on glycogen
metabolism, any impairment in their activity is primed to
affect the energy metabolism in the brain, as seen in different
neurodegenerative diseases. Indeed, noradrenergic dysfunction
during Alzheimer’s disease (Mann et al., 1987) has been linked to
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disruptions in glycogen metabolism (Hertz, 1989; Marien et al.,
2004; Weinshenker, 2008). Other studies showed that epileptic
patients had increased levels of glycogen in the hippocampus,
and sustained seizures led to the synthesis and accumulation of
abnormal glycogen molecules that are resistant to degradation
(Dalsgaard et al., 2007; Dinuzzo et al., 2015). Accumulation of
glycogen was also found in the spinal cord of animal models for
ALS (Li et al., 2019) and epilepsy (Rubio-Villena et al., 2018),
which was due to deteriorated glycogenolysis.
Energy metabolism in astrocytes is not only modulated
by neurons but also affects neuronal activity. Specifically,
glycogen-derived energy supports the clearance of extracellular
potassium and glutamate following neuronal activation (Choi
et al., 2012). Following the astrocyte-neuron lactate shuttle
hypothesis, glucose-derived lactate from astrocytes is transferred
to neurons to maintain neuronal metabolism (Pellerin et al.,
2007), including oxidative phosphorylation and restoration
of a Na+ gradient following glutamatergic neurotransmission
(Sickmann et al., 2005; Gibbs et al., 2007). Inhibition of
astrocyte energy turnover induces deterioration of both neuronal
energy metabolism and extracellular clearance, which can cause
neuronal hyperexcitability (Kreisman and Smith, 1993; Xu
et al., 2013; Kilic et al., 2018). Hence, an initial disturbance
in neuron-astrocyte interactions may create a vicious cycle of
disease development through positive feedback loops, resulting
in augmented neuronal disfunction.
GLIA AS A THERAPEUTIC TARGET FOR
TREATING NEURODEGENERATION
Glial cells make up an integral part of the CNS architecture
and are critical for the maintenance of healthy brain function.
In recent years the field has shifted from viewing glial cells as
passive ‘‘housekeeping’’ cells to becoming active participants in
brain function and modulation of neuronal output. In addition
to their functions in the healthy brain, a growing body of
evidence suggests glia are implicated in the progression of
neurodegeneration, either through the loss of normal function or
the introduction of abnormal function (Sofroniew and Vinters,
2010). Moreover, there is cumulative experimental evidence
suggesting that functional and genetic alterations in glia are
driving disease pathogenesis, see De Strooper and Karran (2016)
and Gleichman and Carmichael (2020) for detailed reviews.
For these reasons, neuron-glia transmission can no longer be
viewed as a passive method of communication and must be seen
as an active and important signaling thread that joins many
neurodegenerative disorders.
Current therapeutic strategies for treating neurodegeneration
include targeting the ApoE4 signaling pathway, which is the
greatest risk factor for AD and primarily expressed in glial
cells, and nicotinamide adenine dinucleotide (NAD), which is
thought to regulate inflammatory repair processes (Blacher et al.,
2015; Roboon et al., 2019). Indeed, Sawmiller et al. (2019)
reported that disrupting the ApoE signaling cascade ameliorated
cerebral Aβ and tau pathologies, including neuronal apoptosis
and synaptic loss in a mouse model of AD. Moreover, the deletion
of CD38, the enzyme that hydrolyzes NAD and controls its
bioavailability, was recently found to suppress glial activation
and neuroinflammation in a mouse model for demyelination
(Roboon et al., 2019). As levels of NAD reduce with age, this
strategy represents a promising target for MS, AD, and other
age-related neurodegenerative disorders.
Another therapeutic strategy includes astrocyte-targeted
production of interleukin-6, which has been shown to reduce
the activation of both astrocytes and microglia and delay
demyelination of neurons in a mouse model of MS (Petkovi ć
et al., 2016). Moreover, targeting the histaminergic system with
anti-histamine proved as a strategy that can preserve myelin
and initiate myelination in animal models of MS (Mei et al.,
2014, 2016; Liu et al., 2016), and this has now been tested in a
randomized control trial of 50 MS patients with promising results
(Green et al., 2017).
Recently, strategies directed towards targeting the astrocytic
glutamate transporter EAAT2 proved to be beneficial in
alleviating the hyperexcitability symptoms associated with
some neurodegenerative diseases and decrease the level of
neurodegeneration in animal models of epilepsy (Kong et al.,
2012, 2014; Goodrich et al., 2013; Zaitsev et al., 2019), ALS
(Kong et al., 2014), PD (Chotibut et al., 2014; Hsu et al., 2015)
and HD (Sari et al., 2010). Moreover, modulation of astrocytic
energy metabolism via inhibition of lactate dehydrogenase (Sada
et al., 2015; Rosati et al., 2018) or via ketonic diet (Valdebenito
et al., 2016) had a neuroprotective effect in both animal models
of PD (Shaafi et al., 2016), and patients with HD (Adanyeguh
et al., 2015) and epilepsy (van Berkel et al., 2018). Also,
treatments that targeted the suppression of the inflammatory
NF-κB pathway by increasing the expression of neurotrophic
growth factor IGF-1 (Hu et al., 2018), or decreasing microglial
proliferation (Martínez-Muriana et al., 2016), postponed the
onset and slowed down the progression of motoneuron death in
a mouse model of ALS.
CONCLUSION
The etiology of neurodegeneration is still unclear, however recent
studies established that lack of glial support and dysregulation
in neuron-glia interactions are central for disease initiation and
progression. More research is needed to address key questions
on neuronal-glia interactions, such as why do astrocytes contact
some synapses and not others, and how does this communication
change over developmental stages or with the progression of
the disease?
We know neuron-glia interactions are dynamic, can be
altered by neuronal activity, and can change throughout life
(Bernardinelli et al., 2014). However, during neurodegeneration,
alterations in neuron-glia interactions take place slowly and their
source is largely unknown. While glial modulation of synaptic
morphology and function has been heavily investigated in the
past decade, the neuron-glia communication processes that affect
glial function are still unclear. Molecular, cellular, and genetic
approaches can be employed to investigate these communication
mechanisms, as addressing this gap will provide novel targets for
much needed therapeutic intervention.
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